| Item Type | Name |
|
Concept
|
Hypolipidemic Agents
|
|
Academic Article
|
Does differing metabolism by cytochrome p450 have clinical importance?
|
|
Academic Article
|
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
|
|
Academic Article
|
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents.
|
|
Academic Article
|
A look to the future: new treatment guidelines and a perspective on statins.
|
|
Academic Article
|
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
|
|
Academic Article
|
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
|
|
Academic Article
|
Management of hypercholesterolaemia in postmenopausal women.
|
|
Academic Article
|
Combination therapy for dyslipidemia: safety and regulatory considerations.
|
|
Academic Article
|
Combination lipid-lowering therapy in diabetes.
|
|
Academic Article
|
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.
|
|
Academic Article
|
Comparative effects of lipid-lowering therapies.
|
|
Academic Article
|
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
|
|
Academic Article
|
How low to target LDL?
|
|
Academic Article
|
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
|
|
Academic Article
|
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
|
|
Academic Article
|
Differences between clinical trial efficacy and real-world effectiveness.
|
|
Academic Article
|
High-density lipoprotein metabolism: potential therapeutic targets.
|
|
Academic Article
|
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
|
|
Academic Article
|
Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals.
|
|
Academic Article
|
Biologic therapies for dyslipidemia.
|
|
Academic Article
|
Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II).
|
|
Academic Article
|
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
|
|
Academic Article
|
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
|
|
Academic Article
|
Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors.
|
|
Academic Article
|
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
|
|
Academic Article
|
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
|
|
Academic Article
|
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
|
|
Academic Article
|
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
|
|
Academic Article
|
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
|
|
Academic Article
|
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
|
|
Academic Article
|
Novel targets that affect high-density lipoprotein metabolism: the next frontier.
|
|
Academic Article
|
Safety of aggressive lipid management.
|
|
Academic Article
|
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.
|
|
Academic Article
|
Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction.
|
|
Academic Article
|
Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
|
|
Academic Article
|
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
|
|
Academic Article
|
High-dose statins in acute coronary syndromes.
|
|
Academic Article
|
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
|
|
Academic Article
|
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
|
|
Academic Article
|
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia.
|
|
Academic Article
|
Novel developments in omega-3 fatty acid-based strategies.
|
|
Academic Article
|
Safety considerations with fibrate therapy.
|
|
Academic Article
|
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
|
|
Academic Article
|
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
|
|
Academic Article
|
Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia.
|
|
Academic Article
|
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
|
|
Academic Article
|
Risk for myopathy with statin therapy in high-risk patients.
|
|
Academic Article
|
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
|
|
Academic Article
|
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
|
|
Academic Article
|
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
|
|
Academic Article
|
Reducing the risk of stroke through appropriate targets and treatments.
|
|
Academic Article
|
Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al.
|
|
Academic Article
|
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
|
|
Academic Article
|
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
|
|
Academic Article
|
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
|
|
Academic Article
|
Combination therapy with statins: who benefits?
|
|
Academic Article
|
ETC-1002: a future option for lipid disorders?
|
|
Academic Article
|
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
|
|
Academic Article
|
Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments.
|
|
Academic Article
|
Overcoming toxicity and side-effects of lipid-lowering therapies.
|
|
Academic Article
|
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.
|
|
Academic Article
|
Reducing residual cardiovascular risk with novel therapies.
|
|
Academic Article
|
Recent advances and emerging therapies in management of dyslipidemias.
|